BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Biotech Bay

  Eiger BioPharma Announces Pricing of Public Offering of Common Stock

  Eiger BioPharma today announced the pricing of its underwritten public offering of 1,854,749 shares of its common stock at a price of $10.00 per share, before underwriting discounts and commissions.

  October 27, 2017

   · 

  3 min read
• 

  Business

  Zynex Growth Leads to a New Corporate HQ

  Zynex will be moving its corporate headquarters to 9555 Maroon Circle, Englewood CO 80112.

  October 27, 2017

   · 

  2 min read
• Pharm Country

  Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

  The SUNBEAM study evaluated two doses (1 mg and 0.5 mg) of oral ozanimod in 1,346 patients with RMS in 20 countries treated for at least one year.

  October 27, 2017

   · 

  8 min read
• BioMidwest

  ACIST Medical Systems Announces Approval and Launch of Next-Generation FFR System

  The RXi Mini System will debut at the 29th Transcatheter Cardiovascular Therapeutics scientific symposium in Denver, Colorado.

  October 27, 2017

   · 

  3 min read
• Biotech Beach

  PharmaCyte Biotech Update on Shareholder Call

  Mr. Waggoner will also report on the progress being made by PharmaCyte in its diabetes program and ascites program.

  October 27, 2017

   · 

  3 min read
• 

  Zebra Medical Vision Wants to Offer AI-Assisted Imaging Scans for $1

  This is another step in the company’s quest to provide high quality, affordable care to the world’s population.

  October 27, 2017

   · 

  3 min read
• Genetown

  Unum Therapeutics to Present New Data on Its Antibody-Coupled T Cell Receptor (ACTR) Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  Unum Therapeutics announced that the Company will be presenting on its Antibody-Coupled T cell Receptor (ACTR) platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held in Philadelphia, PA on October 27-30, 2017.

  October 27, 2017

   · 

  3 min read
• Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis

  Interim data from more than 570 patients at one and three months of treatment with ALKS 8700 were presented at MSParis2017.

  October 27, 2017

   · 

  7 min read
• Genetown

  Treatment Effects Maintained Over Five Years in Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme’s Lemtrada (Alemtuzumab) in Extension Study After Switching from Interferon Beta-1a

  These investigational data are being presented during the 7th Joint Meeting of the European and Americas Committees for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS).

  October 27, 2017

   · 

  15 min read
• Drug Development

  Epizyme Presents Data from a Phase I Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  First presentation of pediatric dose escalation data in tazemetostat, showing favorable safety and tolerability with promising anti-tumor activity.

  October 27, 2017

   · 

  6 min read